Document is current
Any future updates will be listed below
-
Authors
Pereira, Vanessa https://orcid.org/0000-0002-9067-4038
Barreiros-Mota, Inês
Cortez, Filipa https://orcid.org/0000-0003-0521-9629
Castela, Inês
Teixeira, Diana
Calhau, Conceição
Camila Dias, Cláudia
Moreira-Rosário, André
Silvestre, Marta P. https://orcid.org/0000-0001-9327-2897
-
Funding
Funding for this research was provided by:
NOVA | Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa (RISE - LA/P/0053/2020, RISE - LA/P/0053/2020, RISE - LA/P/0053/2020, RISE - LA/P/0053/2020, RISE - LA/P/0053/2020, RISE - LA/P/0053/2020, RISE - LA/P/0053/2020, RISE - LA/P/0053/2020)
Farmodiética S.A. Farmodiética is a Pharmaceutical Manufacturing, and Pharmaceuticals company_reader located in PT
- License Information
-
More Information
Article History
Received: 5 January 2024
Revised: 30 April 2024
Accepted: 21 May 2024
First Online: 6 June 2024
Competing interests
: Vanessa Pereira and Filipa Cortez work at Farmodiética S.A., one of the study sponsors. The sponsor provided support in the form of salaries for the author (Vanessa Pereira) and research materials but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the paper. The other researchers do not have any relationship with this sponsor.
: This trial was registered at clinical trials.gov under the identifier NCT04192357. The recruitment and data collection of this study have already been completed. The study was approved by the Ethics Committee of the NOVA Medical School (Lisbon, Portugal) (CEFCM Approval Number: 108/2018) and was registered at (NCT04192357) before participants’ recruitment. All participants provided written informed consent in accordance with the principles of the Declaration of Helsinki. Written informed consent has been obtained from the patients to publish this paper.
